Medable Platform Speeds Diabetes Study Startup By 50%

One of the top 10 pharmaceutical companies reached out to Medable for assistance with their Phase III diabetes study within the weight loss market. Their primary aim was to slash the client's average study setup timeline from 16-20 weeks to eight weeks, marking a significant reduction of over 50%.

However, the client was confronted with formidable competition in the extensively covered weight loss market and is eager to expedite their entry into the market. As a result, the top pharma approached Medable for support. The teams then collaborated to conduct a thorough examination of the existing trial startup procedures, pinpointing areas where enhancements in technology and processes could streamline operations and establish new fundamental startup guidelines for the trial.

Access the case study below to see how the top pharma was able to integrate the functionalities of the Medable platform for tasks such as screening, data collection, electronic Clinical Outcome Assessments (eCOAs), and other critical components.